UK markets open in 4 hours 52 minutes

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.27-0.44 (-5.05%)
At close: 04:00PM EDT
8.30 +0.03 (+0.36%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.71
Open8.77
Bid9.00 x 1000
Ask9.02 x 800
Day's range8.27 - 8.77
52-week range1.33 - 11.11
Volume416,505
Avg. volume440,338
Market cap392.617M
Beta (5Y monthly)2.13
PE ratio (TTM)N/A
EPS (TTM)-2.05
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.50
  • Simply Wall St.

    Shattuck Labs Full Year 2023 Earnings: Beats Expectations

    Shattuck Labs ( NASDAQ:STTK ) Full Year 2023 Results Key Financial Results Net loss: US$87.3m (loss narrowed by 14...

  • GlobeNewswire

    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful execu

  • GlobeNewswire

    Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

    - Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting – - Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m